Proposed FDA Rule Could Bring Failure-To-Warn Liability

Law360, New York (January 23, 2014, 1:36 AM EST) -- A rule proposed by the U.S. Food and Drug Administration in early November could increase generic drug manufacturers’ exposure to legal liability. Specifically, the FDA is proposing to amend 21 C.F.R. part 314 — Applications for FDA Approval to Market a New Drug, in order to allow generic drug manufacturers to update labels independently from brand-name manufacturers. According to the FDA, this rule would operate to permit generic drug manufacturers to update drug labels themselves when they acquire new information about a drug and submit a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.